Quidel Corporation  

(Public, NASDAQ:QDEL)   Watch this stock  
Find more results for Ken Brown
+2.03 (9.64%)
Real-time:   2:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.67 - 23.24
52 week 13.21 - 23.24
Open 21.67
Vol / Avg. 164,883.00/121,691.00
Mkt cap 753.40M
P/E     -
Div/yield     -
EPS -0.40
Shares 32.33M
Beta 0.73
Inst. own 97%
Aug 2, 2016
Quidel Investor and Analyst Luncheon Event During AACC - 11:00AM EDT - Add to calendar
Jul 27, 2016
Q2 2016 Quidel Corp Earnings Call - Webcast
Jul 27, 2016
Q2 2016 Quidel Corp Earnings Release
May 17, 2016
Quidel Corp Annual Shareholders Meeting
May 10, 2016
Quidel Corp at Bank of America Merrill Lynch Health Care Conference - Webcast
May 4, 2016
Quidel Corp Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -6.85% -3.10%
Operating margin -6.88% 1.40%
EBITD margin - 13.32%
Return on average assets -3.52% -1.42%
Return on average equity -6.63% -2.62%
Employees 624 -
CDP Score - -


12544 High Bluff Dr Ste 200
SAN DIEGO, CA 92130-3050
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company's diagnostic testing solutions primarily include applications in infectious diseases, women's health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Douglas C. Bryant President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Randall J. Steward Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Robert Joseph Bujarski J.D. Senior Vice President - Business Development, General Counsel and Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Michael D. Abney Jr. Senior Vice President - Distribution
Age: 52
Bio & Compensation  - Reuters
Werner Kroll Ph.D Senior Vice President,R&D
Age: 59
Bio & Compensation  - Reuters
Edward Keith Russell Senior Vice President - Global Commercial Operations
Age: 48
Bio & Compensation  - Reuters
John D. Tamerius Ph.D. Senior Vice President - Strategic and External Affairs
Age: 70
Bio & Compensation  - Reuters
Charles P. Slacik CPA Director
Age: 61
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 68
Bio & Compensation  - Reuters